Core Insights - The article highlights the rapid advancement of Chinese medical device companies, particularly Yuyue Medical, in overcoming technological barriers and moving towards the mid-to-high end of the global industrial chain [2] - Yuyue Medical's continuous glucose monitoring system (CGM) has received CE certification under the EU Medical Devices Regulation (MDR), marking a significant milestone for the company and the Chinese medical device industry [2][3] Group 1: Product Development and Market Position - Yuyue Medical has focused on respiratory therapy, blood glucose management, POCT, and home health testing, supported by strong R&D capabilities [3] - The blood glucose management and POCT segment has experienced double-digit growth since 2022, showcasing the successful transformation of Yuyue Medical's innovative achievements [3] - The "Anytime" series of CGM products, particularly Anytime 4 and Anytime 5, have been launched, expanding the applicability of blood glucose monitoring in various settings and achieving significant advancements in performance [3][4] Group 2: Market Expansion and International Strategy - Yuyue Medical aims to accelerate its overseas expansion, focusing on building international teams and enhancing market access for its blood glucose management business [6] - The company has established R&D centers in strategic locations such as Italy, the Netherlands, and Germany, and has subsidiaries in the U.S., Brazil, Thailand, and Indonesia, creating a comprehensive network across over 130 countries [6] - The global CGM market is expected to grow significantly, with projections indicating a market size of $35.44 billion by 2032, positioning China as a key growth driver due to favorable policies and demand [7]